Replimune-free? No—separate development: a Phase 2 trial report indicates mezagitamab, an investigational antibody for immune thrombocytopenia (ITP), significantly increased platelet counts in treated patients. The study positions the therapy as a rapid-acting option for a disease marked by immune-mediated platelet destruction and bleeding risk. ITP is an autoimmune disorder where platelet levels fall due to both increased destruction and impaired production, leading to unpredictable bleeding complications. The trial’s results focus on the ability of the antibody to drive measurable platelet recovery. For stakeholders, the update is relevant to the competitive landscape of ITP therapeutics, where durable response and speed of platelet normalization remain key differentiators. It also sets a benchmark for future Phase 3 studies around response durability and safety. The findings provide a near-term signal to clinicians and investors evaluating the next wave of antibody-based treatments in hematology.